Pharmacoeconomic Guidelines Around The World

This section of the ISPOR website, "Pharmacoeconomic Guidelines Around the World" provides the following:

• A comparative table of 33 guideline key features. The key features of the guidelines are: 1) type, 2) title and year of the document, 3) affiliation of authors, 4) main policy objective, 5) standard reporting format included, 6) disclosure of funding/ author's interests, 7) target audience, 8) perspective, 9) indication, 10) target population, 11) subgroup analysis, 12) choice of comparator, 13) time horizon, 14) assumptions required, 15) preferred analytical technique, 16) costs to be included, 17) source of costs, 18) modeling, 19) systematic review of evidences, 20) preference for effectiveness over efficacy, 21) preferred outcome measure, 22) preferred method to derive utility, 23) Equity issue stated, 24) discounting costs, 25) discounting outcomes, 26) sensitivity analysis- parameters and range, 27) sensitivity analysis- methods, 28) presenting results, 29) incremental analysis, 30) total C/E, 31) portability of results (generalizability), 32) financial impact analysis, 33) Mandatory or recommended or voluntary
  
• Country-specific guidelines’ key features (33) as well as hyperlinks or full text of the guideline (as copyright permission allows) or publication reference including a map of the country

Guidelines listed are dated based on the publication date of the document and categorized as follows:

1. Published PE Recommendations: they are country-specific economic evaluation guidelines or recommendations published by experts in the field but are not “officially” recognized or required by the health care decision-making bodies/entities in this country/region for reimbursement.
2. PE Guidelines:: they are country-specific “official” guidelines or policies concerning economic evaluation that are recognized or required by the health care decision-making bodies/entities in this country/region for reimbursement.
3. Submission Guidelines: they are country-specific “official” guidelines or policies concerning drug submission requirements with an economic evaluation part/section and are required by the health care decision-making bodies/entities in this country/region for reimbursement.

COUNTRY-SPECIFIC PHARMACOECONOMIC GUIDELINES